Lidoject (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, stopping the rapid influx of sodium ions needed for depolarisation. This stabilises the neuronal membrane and prevents the transmission of pain signals, producing a reversible loss of sensation.

The appropriate dose of Lidoject is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical context. Dosing guidelines are provided in the product’s prescribing information and must be followed by the healthcare professional.

Safety data for lidocaine during pregnancy and lactation are limited. Use of Lidoject in pregnant or nursing women should only occur when the potential benefit justifies any potential risk to the fetus or infant, and after careful evaluation by the prescriber.

To order Lidoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Lidoject (lidocaine) is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for short procedures. Compared with ester‑type agents such as procaine, lidocaine has a lower incidence of allergic reactions and a more predictable pharmacokinetic profile.

Lidoject should be stored at controlled room temperature, protected from light and moisture, and kept in its original packaging. Do not freeze the product. Follow standard aseptic techniques when preparing the injection to maintain sterility.

Lidoject is administered by a qualified healthcare professional via intravenous or subcutaneous injection. The injection site is selected based on the intended area of anesthesia, and the dose is injected slowly while monitoring the patient for any adverse reactions.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias, methemoglobinemia, and central nervous system toxicity such as seizures. Immediate medical attention is required if any of these events occur during or after administration.

Lidoject should be avoided in patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled epilepsy, or significant hepatic impairment that could increase drug accumulation.